Introduction
Epilepsy is a common and chronic neurological disorder that imposes a substantial burden on individuals and society as a whole. The initial diagnosis of epilepsy is associated with costs of diagnostic procedures, inpatient admission and related loss of income [1, 2] . Even after a first seizure or with newly established diagnosis of epilepsy, patients are affected by social stigma, reduced employment opportunities and impaired quality of life for themselves and their caregivers, resulting in increased indirect and intangible costs [3] [4] [5] [6] [7] [8] .
Antiepileptic drugs (AEDs) are the central and crucial element in the treatment of epilepsy patients. The majority of patients require an anticonvulsant treatment for an extended period of time[ 1 2 _ T D $ D I F F ] , and up to 30% of patients remain refractory, despite optimal medical treatment [9, 10] . Economic evaluations are particularly important in patients with newly diagnosed and active epilepsy, as these patients account for a high proportion of total costs [11] [12] [13] [14] [15] .
To allow for the best possible therapy in patients with neurological diseases, the German Neurological Society (Deutsche Gesellschaft fü r Neurologie [DGN] , Berlin) has been regularly publishing clinical practice guidelines since 2002. In general, guidelines are viewed by physicians as helpful in terms of increasing the quality of patient care, education and the presentation of information without bias [16, 17] . However, there Method: This retrospective, population-based analysis was performed on patient data of 4.1 million insurants from the German statutory health insurance. Prevalent and incident cases in adults were identified based on ICD-10 codes, using a hierarchical diagnosis selection algorithm. The first anticonvulsive agent in a newly diagnosed epilepsy patient was validated against the clinical practice guideline. Results: We determined an annual crude prevalence rate in adults between 0.946% and [ 1 1 _ T D $ D I F F ] 1.090% and incidence rates of at least 156 per 100,000. A significant increase in guideline compliant monotherapy was found in patients with a focal epilepsy syndrome, while, among patients with idiopathic generalised epilepsies, the share of guideline noncompliant monotherapy increased. is no data on the implementation of clinical practice guidelines regarding anticonvulsive treatment in epilepsy patients. In 2007, the pivotal SANAD studies [18, 19] and a randomised controlled trial comparing carbamazepine extended-release with levetiracetam [20] were published. As a consequence, the German clinical practice guidelines on epilepsy published in 2008 [21, 22] named certain drugs as the first choice (i.e. lamotrigine and levetiracetam in focal epilepsy), warned against using strong enzyme-inducing drugs (i.e. carbamazepine, phenytoin or phenobarbital) and warned against use of valproate in women of childbearing age. Table 1 shows anticonvulsive treatment options according to authorisation status of each individual drug for initial monotherapy as of January 1st, 2008 and recommendations from the guidelines. Oxcarbazepine was assumed as first choice in focal epilepsy as there was non-significant advantage of [ 1 3 _ T D $ D I F F ] lamotrigine compared with oxcarbazepine in the SANAD study [19] , furthermore [ 1 4 _ T D $ D I F F ] oxcarbazepine was recommended by the Vademecum Antiepilepticum [23] .
The aim of this study is to examine the implementation of the clinical practice guidelines ''first epileptic seizure and epilepsy in adulthood'' [21] published in 2008 for patients with newly diagnosed epilepsy between 2008 and 2014. This evaluation is performed on the research database of Gesundheitsforen Leipzig that covers more than 4.1 million German insurants in the statutory health insurance (Gesetzliche Krankenversicherung [GKV] ). This top-down approach, for the first time, allows for the examination of a high number of patients affected by epilepsy in Germany.
Methods
This retrospective analysis was conducted on the research database of Gesundheitsforen Leipzig that provides access to data of statutory health insurance from approximately 4.1 million insurants (i.e. 5.1% of the overall German population). Information related to in-and outpatient diagnoses, medication, costs, procedures and demographics is regularly collected and routinely inspected for outliers, data errors and changes over the years. The research database is continuously evaluated for its representativeness by comparison with the annual publications of the German Federal Social Insurance Office (Bundesversicherungsamt [BVA]) and has already been used for epidemiological studies [24] . This analysis was performed on consecutive insurance years from 2007 to 2014 in adult patients (18 years of age).
Identification of study population with epilepsy
The study population was identified by the presence of ICD-10-GM (10th revision of the International Statistical Classification of Diseases and Related Health Problems, German Modification, www.dimdi.de) codes for epilepsy (G40*). As there are no significant differences in epilepsy codes between the ICD-10 and ICD-10-GM systems at the third or fourth digit level, the term ICD-10 is used throughout this article. To ensure the validity of epilepsy classification, a patient has to meet the requirement of an ensured diagnosis, which is composed of at least one inpatient G40* diagnosis or two confirmed outpatient G40* diagnoses. A similar process of epilepsy case identification was used in Canadian evaluations based on ICD-10 coding and validation showed sensitivity and positive predictive value of up to 98% [25] [26] [27] [28] [29] . To avoid bias due to psychiatric comorbidities, patients with organic, including symptomatic, mental disorders (F00-F09), mental and behavioural disorders due to psychoactive substance use (F10-F16, F18-F19), schizophrenia, schizotypal and delusional disorders (F20-F29), manic episodes (F30) and bipolar affective disorder (F31) were excluded from the analysis.
Identification of newly diagnosed epilepsy
To analyse the implementation of the clinical practice guidelines [21] , newly diagnosed epilepsy patients had to be identified. Four different methods, with increasingly stringent inclusion criteria, were applied to identify newly diagnosed patients during the whole observation period from 2008 to 2014. Method 1 assigns a newly diagnosed epilepsy to patients if there has been no ensured epilepsy diagnosis in the previous year of observation (i.e. oneyear-incidence). Method 2 attributes a newly diagnosed epilepsy to patients if there is no ensured epilepsy coding in the preceding two years (i.e. two-year-incidence). Method 3 attributes a newly diagnosed epilepsy to patients if neither an ICD-10 diagnosis of epilepsy nor treatment with AEDs is present in the preceding year of identification (i.e. one-year-incidence-noAED). Method 4 accounts for patients where neither an ICD-10 diagnosis of epilepsy nor treatment with AEDs is present for two years (i.e. two-year-incidence-noAED). Thus, the incidence for method 1 and 3 can be provided from 2008 onwards, while, for method 2 and 4, it can be provided from 2009 onwards.
Determination of epilepsy syndromes
The determination of an epilepsy syndrome based on ICD-10 diagnoses is complicated by the mixture of seizure classification with the classification of syndromes. Furthermore, there is no exact correspondence between ICD-10 codes for epilepsy and the epilepsy syndrome [30] and seizure [31] classification defined by the International League Against Epilepsy (ILAE) in the eighties or with the latest terminology and concepts for organisation of seizures and epilepsies, revised in 2009 [32] . The ICD-10 code was used to determine four main groups with focal or structuralmetabolic epilepsy corresponding to ICD-10 G40.1 or G40.2, idiopathic or genetic generalised epilepsy corresponding to ICD-10 G40.3, specific epilepsy syndromes corresponding to ICD-10 G40.0, G40.4 and G40.5, and unknown epilepsy syndromes corresponding to ICD-10 G40.6 to G40.9. The basic assumption is to overrule less specific diagnoses by more specific diagnosis. For this purpose, we developed a hierarchical approach to specify a set of epilepsy diagnoses. The hierarchical diagnosis selection algorithm is represented in Fig. 1 . If a patient presented with both G40.1/2 and G40.3 then the patient was assigned to the majority class of diagnoses. An additional group of ''unspecific G40.1/2/3'' was introduced if the selection was ambiguous. Finally, patients having only ICD-10 diagnoses G40.6 to G40.9 were assigned to the group of ''unknown epilepsy syndrome''. Patients with ICD-10 G40.0 were not further analysed, as this code for idiopathic focal epilepsies is predominantly present in children and adolescents. 
Identification of treatment patterns
Patients receiving one prescription of antiepileptic drugs (AEDs), corresponding to ATC-codes N03A, were considered as treated. Patients receiving one AED per year were considered as treated with a monotherapy, while for those receiving two different AED prescriptions per year, a polytherapy was assumed. Patients were assigned to four different therapy groups as polytherapy (patients receiving more than one AED within one year), no AED (patients receiving no AED within one year upon diagnosis), guideline compliant monotherapy (patients receiving monotherapy according to the guideline as outlined in Table 1 ) and guideline noncompliant monotherapy (patients receiving monotherapy in disagreement with the guideline).
Statistical analysis
All data was managed and analysed using an anonymous patient code, in order to comply with data protection regulations. Data were analysed with SQL Server 2008 R2, MS Excel and R [35] . The annual crude prevalence in adults was calculated based on the number of cases in the study years 2008-2014 divided by the total number of insurants per year. Incident cases were identified using the above algorithms and annual incidence rates were calculated for the period 2008-2014 using as reference the person-years of exposure in the insurant population. Chi-square tests were performed to assess the distribution of patients with guideline compliant and noncompliant therapy between 2008 and the following years.
Results

Identification of prevalent and newly diagnosed epilepsy patients
According to the case definition with at least one inpatient ICD-10 G40* diagnosis or two confirmed outpatient ICD-10 G40* diagnoses, we determined an annual prevalence rate in adults between 0.946% (15,940 epilepsy patients per 1,684,618 insurants, mean age 50. Table 2 . The amount of incident patients varies by 30% from method 1 to method 4. Further analysis on diagnosis structure and guideline implementation was performed on incident patients as identified by method 3. One-year-incidence Two-year-incidence One-year-incidence-noAED Two-year-incidence-noAED Methods of incidence determination: 1. One-year-incidence in patients with no ensured epilepsy coding in the preceding year; 2. Two-year-incidence in patients with no ensured epilepsy coding in the preceding two years; 3. One-year-incidence-noAED in patients with neither an ICD-10 diagnosis of epilepsy or treatment with AEDs in preceding year. 4. Two-year-incidence-noAED in patients with neither an ICD-10 diagnosis of epilepsy or treatment with AEDs in preceding two years.
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Distribution of epilepsy syndromes
Epilepsy syndromes of prevalent and incident patients are classified using the hierarchical approach on ICD-10 diagnoses, as presented earlier (see Fig. 1 ). The distribution of epilepsy syndromes within the prevalent epilepsy population, as shown in Fig. 3 , reveals a trend towards upcoding of specific G40.1/2 diagnoses over the years [ 1 9 _ T D $ D I F F ] from 19.8% to 23.1%, whereas the remaining group of unclear diagnoses G40.6-9 decreased [ 2 0 _ T D $ D I F F ] from 55.5% to 50.9%. A similar trend can be observed within the one-yearincidence-noAED population (see Fig. 4 ). The fraction of patients with an ICD-10 code of G40.1/2 increased from 30.5% in 2008 to 35.6% in 2014, while coding of unclear epilepsy syndromes decreased from 42.9% in 2008 to 39.6% in 2014. Overall, there is a trend towards more specific ICD coding, as the fraction of G40.1/2 and G40.5 diagnoses was higher in newly diagnosed patients than in prevalent cases. Furthermore, the fraction of unknown epilepsy (G40.6-9) was highest in the prevalent population (around 52%) compared to the incident population (around 42%). Fig. 5 shows the fraction of newly diagnosed patients receiving guideline compliant monotherapy (as outlined in Table 1) , guideline noncompliant monotherapy, no AED, or polytherapy in
Anticonvulsant treatment in patients with newly diagnosed epilepsy
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GL=guideline; AED = anƟepilepƟc drug 20% 33% 39% 44% 24% 20% 22% 15% 15% 15% 10% 6% 17% 18% 24% 20% 31% 20% 14% 11% 18% 22% 25% 28% 31% 29% 40% 41% 12% 10% 6% 7% 38% 34% 34% 32% 51% 49% 46% 47% 41% 42% 37% 37% 68% 68% 67% 69% Tables 1 and 2 provide patients numbers for each hierarchy group and prescription pattern.
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Discussion
This is the first nationwide study using anonymised health insurance data to analyse implementation of clinical practice guidelines for epilepsy in newly diagnosed patients in Germany. We were able to present recent data from 2007 to 2014, to demonstrate an increase in guideline compliant therapy over time, to confirm other studies on prevalence using a top-down approach [33] [34] [35] and to give estimations of ICD-10 coding of potentially newly diagnosed epilepsy.
Patients with newly diagnosed epilepsy present an important patient group, as their response to initial anticonvulsive therapy will determine the future course of the disease. The proportion of guideline compliant monotherapy in focal epilepsies increased from 20% in 2008 to 44% in 2014, while the proportion decreased in idiopathic generalised epilepsies (IGE) from 24% to 15%. However, the latter is due to increased prescriptions of levetiracetam that are not licensed for initial monotherapy in IGE. A survey [36] among members of the German ILAE branch has shown that a large majority of doctors ignore the existing authorisation status and treat IGE patients with levetiracetam in initial monotherapy. We could also demonstrate a decrease in carbamazepine prescriptions as the mainly used strong enzyme-inducing AEDs. This is consistent with other European and German studies [33, [37] [38] [39] [40] on prescription patterns in epilepsy that show a strong trend in favor of non-enzyme-inducing drugs.
Overall, the majority of patients were treated with AEDs regarded as the first choice by the guideline. However, reasons not to use first choice AEDs in all patients should be taken into consideration, as AEDs such as gabapentin, pregabalin and carbamazepine are indicated for neuropathic pain; zonisamide and topiramate, are indicated for obesity; and valproate and topiramate are indicated for migraine comorbidity. Such prescriptions are in accordance with the guidelines, since these AEDs are selected according to the needs of patients -namely, compatibility and the influence of comorbidities [21] . However, such possible intentions of physicians cannot be proved, as, in a top-down approach used in analysing health insurance data, there is no possibility of tracking back the individual decision in each patient. As the guidelines recommend levetiracetam and lamotrigine as first-line anticonvulsants in focal epilepsies, one should also expect an increase in the share of lamotrigine. However, the share of lamotrigine remained almost unchanged from 2008 to 2014 in Germany. This might be due to favorable properties of levetiracetam and not due to guideline adherence. Overall, it is not feasible to prove a causal relationship between implementation of the epilepsy guidelines and change in levetiracetam prescription in focal epilepsy. Comparison to other European countries such as the UK, where NICE guidelines [41] [43] . A study from Finland regarding initial monotherapy in the elderly (>65 years) showed low shares of levetiracetam (16%) and of lamotrigine (2%) in 2010-13. This may be well explained by the fact that of the secondgeneration AEDs approved for initial monotherapy (gabapentin, lamotrigine, oxcarbazepine, topiramate, levetiracetam) only oxcarbazepine was subject to full reimbursement [44] . Our findings differ from other German studies on the implementation of guidelines in cardiovascular diseases. Karbach and colleagues [45] interviewed general practitioners finding that only 40% possessed a satisfactory knowledge of the guidelines. In a further analysis of prescription patterns (e.g. thrombocyte aggregation inhibitors, statins, diuretics, ß-blockers) of 15 physicians selected with and without adequate guidance knowledge, no differences were found in the majority of quality indicators regarding the implementation of guidelines. In four of 16 indicators, physicians with inadequate guidance were, surprisingly, performing better than were knowledgeable peers [45] . A top-down study [46] on peripheral arterial disease showed a lack of guideline adherence through the performance of significantly less angiographies and revascularisations in patients with critical limb ischemia. The authors evaluated more than 40,000 patients from an insurance database and were clearly surprised by the underuse of diagnostic and therapeutic procedures [46] . A study from the Kork epilepsy centre [47] in referral patients showed that only in 30% of these patients had sufficient and guideline-conform imaging (MRI). In 70% MRI did not accomplish the requirements of the guidelines due to inappropriately thick slides, too few signal weightings or sequence parameters, a lack of temporal angularisation in spite of the question of temporal lobe epilepsy, or a field strength below 1.5 Tesla. In 10% no MRI imaging at all had been performed [47] . The same applies to referral to epilepsy surgery that takes a mean epilepsy duration at presurgical assessment of 18 years [48] , although referral should be accomplished upon failure of two AED regimens. A recent survey in Austria, Germany and Switzerland on discussing epilepsy-associated risks with patients showed that a high proportion of neurologists and neuropaediatricians discuss restrictions in driving and risks of daily life but defer from discussing SUDEP or suicidal ideation on AEDs with their patients [49] . Possible causes for limitations in guideline implementation include difficulties in leaving older and previously used therapeutic strategies in favour of new guidelines, lack of interest in clinical guidelines, decreased self-efficacy and lack of time [16, 50] .
In summary, this evaluation of health insurance data shows a countrywide increase in guideline implementation regarding initial monotherapy for focal epilepsy. However, this is only one aspect of the guidelines and future studies should also focus on refractory patients and their anticonvulsive treatment or access to epilepsy surgery programmes, as international studies show a delay in referrals [51, 52] .
Despite the careful study design, this retrospective study on health insurance data suffers from certain limitations inherent to such investigations. This study revealed an annual period prevalence for epilepsy between 0.946% (9.46 per 1000) and [ 1 1 _ T D $ D I F F ] 1.090% (10.9 per 1000). This is much higher as compared to a median point prevalence of 5.5 per 1000 (range 5.3-6.3) for an adult European population reported in a systematic review on the epidemiology of epilepsy in Europe [53] . However, our numbers are similar to a prevalence of 9.7 per 1000 in a Norwegian study [34] and to 9.1 per 1000 in a German study [33] , both using a prescription database for their analysis. The overall differences may be due to methodological aspects and the chosen definition of epilepsy. Epidemiological studies focus on the incidence and prevalence of active epilepsy that is defined as patients having at least one seizure in the previous 5 years [53] . Such studies would exclude patients who present to their physicians for AED prescription but are seizure free for more than 5 years. Furthermore, patients discontinuing AEDs upon a long seizure-free interval would be not taken into account, even if their epilepsy would not be considered resolved, as outlined in the last ILAE definition [54] . Such patients were included in our study and might partly explain the discrepancy between the calculated prevalence in this study and epidemiological estimations. Furthermore, we cannot exclude that patients were coded with an ICD-10 diagnosis of epilepsy upon their first seizure, while not yet requiring AED treatment and not fulfilling the ILAE criteria [54] . Furthermore patients with acute symptomatic seizures might be also coded with an ICD-10 diagnosis of epilepsy. Both might explain the high incidence rate of newly ICD-10 coded epilepsy and the substantial fraction of untreated patients. We could demonstrate that changing minor assumptions in the selection algorithm can lead to a marked reduction of patients in the group of newly identified patients. From method 1 to method 4 a reduction of 30% of patients is observable. We assumed that combining a period without AED prescription and without ICD-10 coded epilepsy such as used in method 3 and 4 creates the most reliable subgroups for incidence analysis. An incidence rate of at least 156 per 100,000 in our evaluation exceeds reported incidence rates of 30-140 per 100,000 in epidemiological studies [53] . The reasons for this are certainly similar to those listed above for the prevalence estimates. An increase over time may also be due to improved coding behaviour in recent years or to an increase of epilepsy in the elderly.
Conclusion
Initial monotherapy in adult epilepsy patients with focal epilepsy is increasingly compliant with clinical practice guidelines. Due to the lack of authorisation of LEV for initial monotherapy in generalised epilepsies the share of guideline compliant monotherapy decreased in this patient group. The strength of this study includes the analysis of population-based health insurance data, used for the first time for a longitudinal analysis of guideline implementation in epilepsy. Further evaluations should address the question of whether patients treated in line with the guidelines have a favorable outcome, compared to patients not treated in line with current guidelines. We confirm that we have read Seizure's position on issues involved in ethical publication and affirm that this report is consistent with these guidelines.
